An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
Status:
Active, not recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
This study evaluates the combination of bavituximab and pembrolizumab in the treatment of
gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that
is not yet approved by the FDA, and pembrolizumab known as Keytruda.
There is no expanded access program available for the investigational agents per this
protocol.